Drugs / Inactivated hepatitis A vaccine
Inactivated hepatitis A vaccine
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 32 trials | ||||||
| Phase 3 | NCT06978621 | May → Jun 2025 overdue | hepatitis A virus infection | Chiang Mai University | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03654664 | Jun 2017 → Jun 2019 | hepatitis A virus infection | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 42 trials · 1 met primary | ||||||
| Phase 4 | NCT05526820 | Apr 2021 | chickenpox | Sinovac (Dalian) Vaccine Technology Co., Ltd. | Completed | Met primary |
| Phase 4 | NCT02445703 | May 2014 → Jan 2015 | hepatitis A virus infection, hepatitis B virus infection | Sinovac Biotech Co., Ltd | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 3 | NCT01453348 Comparator | Oct 2011 → Jan 2012 | hepatitis A virus infection, hepatitis B virus infection, meningococcal meningitis | Novartis Vaccines | Completed | No outcome recorded |
| Phase 4 | NCT04953325 Comparator | Jul → Oct 2021 | COVID-19 | Sinovac Research and Development Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT02526550 Background | Jun → Jul 2014 | encephalitis | Siriraj Hospital | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-06-30 | Sinovac Biotech Co., Ltd | Results 一项长达15年的随访研究显示：甲肝灭活疫苗孩尔来福®能提供至少30年的有效保护 sinovac.com ↗
研究结果显示，孩尔来福 ® 接种后各时间点的抗体水平均显著高于对照组，差异有统计学意义。 |
| 2023-04-24 | Sinovac Biotech Co., Ltd | Results 上海市疾控中心研究：SINOVAC科兴甲肝灭活疫苗与其他疫苗同时接种安全性良好 sinovac.com ↗
该项研究显示SINOVAC科兴生产的甲型肝炎灭活疫苗孩尔来福 ® 与其他多种疫苗在16岁以下儿童中同时接种安全性良好。 |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-06-30 | Sinovac Biotech Co., Ltd | 一项长达15年的随访研究显示：甲肝灭活疫苗孩尔来福®能提供至少30年的有效保护 sinovac.com ↗ |
| 2023-04-24 | Sinovac Biotech Co., Ltd | 上海市疾控中心研究：SINOVAC科兴甲肝灭活疫苗与其他疫苗同时接种安全性良好 sinovac.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Inactivated hepatitis A vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01453348 ↗ |
| Known as | HAV | “Inactivated Hepatitis A vaccine (HAV)” NCT02445703 ↗ |
| Known as | HepA | “This study aimed to evaluate the immunogenicity and safety of co-administration with live attenuated varicella vaccine (VarV) and inactivated hepatitis A vaccine (HepA) among...” PMID 36593652 ↗ Jan 2023 |
| Known as | I-HAV | “inactivated vaccine (I-HAV, 2 doses)” NCT06978621 ↗ |
| Known as | inactivated HAV vaccine | “inactivated HAV vaccine (I-HAV) which is recommended as a 2-dose series administered 6 months apart” NCT06978621 ↗ |
| Modality | Vaccine | “Inactivated hepatitis A vaccine” NCT01453348 ↗ |
| Route | Intramuscular | “administered intramuscularly” NCT01453348 ↗ |